Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right Jun 27, 2025 7:30am EDT
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million May 27, 2025 8:01am EDT
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements May 13, 2025 7:30am EDT
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference May 07, 2025 7:30am EDT
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference Apr 02, 2025 7:30am EDT
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements Mar 17, 2025 4:30pm EDT
